nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—Medroxyprogesterone Acetate—uterine cancer	0.444	1	CrCtD
Methylprednisolone—NR3C1—Medroxyprogesterone Acetate—uterine cancer	0.089	0.424	CbGbCtD
Methylprednisolone—NR3C1—Progesterone—uterine cancer	0.059	0.281	CbGbCtD
Methylprednisolone—Medrysone—Medroxyprogesterone Acetate—uterine cancer	0.0236	0.0827	CrCrCtD
Methylprednisolone—Flurandrenolide—Medroxyprogesterone Acetate—uterine cancer	0.0219	0.0769	CrCrCtD
Methylprednisolone—Medrysone—Progesterone—uterine cancer	0.0206	0.0721	CrCrCtD
Methylprednisolone—Hydrocortamate—Medroxyprogesterone Acetate—uterine cancer	0.0205	0.072	CrCrCtD
Methylprednisolone—Cortisone acetate—Medroxyprogesterone Acetate—uterine cancer	0.0199	0.0697	CrCrCtD
Methylprednisolone—Medroxyprogesterone Acetate—Progesterone—uterine cancer	0.0198	0.0695	CrCrCtD
Methylprednisolone—Prednicarbate—Medroxyprogesterone Acetate—uterine cancer	0.0193	0.0677	CrCrCtD
Methylprednisolone—Hydrocortamate—Progesterone—uterine cancer	0.0179	0.0627	CrCrCtD
Methylprednisolone—Cortisone acetate—Progesterone—uterine cancer	0.0173	0.0608	CrCrCtD
Methylprednisolone—Fludrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.0173	0.0606	CrCrCtD
Methylprednisolone—Testolactone—Progesterone—uterine cancer	0.0168	0.059	CrCrCtD
Methylprednisolone—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.016	0.0563	CrCrCtD
Methylprednisolone—Fludrocortisone—Progesterone—uterine cancer	0.0151	0.0528	CrCrCtD
Methylprednisolone—Hydrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.0141	0.0494	CrCrCtD
Methylprednisolone—ABCB1—Progesterone—uterine cancer	0.0137	0.0654	CbGbCtD
Methylprednisolone—Prednisolone—Progesterone—uterine cancer	0.0128	0.0449	CrCrCtD
Methylprednisolone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0124	0.0592	CbGbCtD
Methylprednisolone—Hydrocortisone—Progesterone—uterine cancer	0.0123	0.0431	CrCrCtD
Methylprednisolone—ABCB1—Dactinomycin—uterine cancer	0.0109	0.0519	CbGbCtD
Methylprednisolone—CYP3A4—Progesterone—uterine cancer	0.00823	0.0392	CbGbCtD
Methylprednisolone—ABCB1—Etoposide—uterine cancer	0.00614	0.0293	CbGbCtD
Methylprednisolone—ABCB1—Doxorubicin—uterine cancer	0.00419	0.02	CbGbCtD
Methylprednisolone—CYP3A4—Etoposide—uterine cancer	0.00368	0.0175	CbGbCtD
Methylprednisolone—CYP3A4—Doxorubicin—uterine cancer	0.00251	0.012	CbGbCtD
Methylprednisolone—Medroxyprogesterone Acetate—AKR1C3—uterine cancer	0.000261	0.167	CrCbGaD
Methylprednisolone—Exemestane—CYP19A1—uterine cancer	0.000241	0.154	CrCbGaD
Methylprednisolone—Testolactone—CYP19A1—uterine cancer	0.00023	0.147	CrCbGaD
Methylprednisolone—Medroxyprogesterone Acetate—PGR—uterine cancer	0.000145	0.0926	CrCbGaD
Methylprednisolone—Fluticasone Propionate—PGR—uterine cancer	0.000144	0.0918	CrCbGaD
Methylprednisolone—Betamethasone—PGR—uterine cancer	0.000132	0.0841	CrCbGaD
Methylprednisolone—Dexamethasone—CYP11A1—uterine cancer	0.000102	0.0649	CrCbGaD
Methylprednisolone—Medroxyprogesterone Acetate—ESR1—uterine cancer	9.16e-05	0.0585	CrCbGaD
Methylprednisolone—Betamethasone—CYP19A1—uterine cancer	9.04e-05	0.0577	CrCbGaD
Methylprednisolone—Infestation—Etoposide—uterine cancer	8e-05	0.00137	CcSEcCtD
Methylprednisolone—Infestation NOS—Etoposide—uterine cancer	8e-05	0.00137	CcSEcCtD
Methylprednisolone—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	7.95e-05	0.00136	CcSEcCtD
Methylprednisolone—Urticaria—Progesterone—uterine cancer	7.92e-05	0.00136	CcSEcCtD
Methylprednisolone—Acute coronary syndrome—Etoposide—uterine cancer	7.88e-05	0.00135	CcSEcCtD
Methylprednisolone—Abdominal pain—Progesterone—uterine cancer	7.88e-05	0.00135	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Etoposide—uterine cancer	7.84e-05	0.00134	CcSEcCtD
Methylprednisolone—Myocardial infarction—Etoposide—uterine cancer	7.84e-05	0.00134	CcSEcCtD
Methylprednisolone—Fatigue—Medroxyprogesterone Acetate—uterine cancer	7.79e-05	0.00133	CcSEcCtD
Methylprednisolone—Malaise—Dactinomycin—uterine cancer	7.79e-05	0.00133	CcSEcCtD
Methylprednisolone—Dexamethasone—PGR—uterine cancer	7.66e-05	0.0489	CrCbGaD
Methylprednisolone—Skin exfoliation—Epirubicin—uterine cancer	7.65e-05	0.00131	CcSEcCtD
Methylprednisolone—Inflammation—Doxorubicin—uterine cancer	7.64e-05	0.00131	CcSEcCtD
Methylprednisolone—Fluid retention—Epirubicin—uterine cancer	7.61e-05	0.0013	CcSEcCtD
Methylprednisolone—Neuropathy—Epirubicin—uterine cancer	7.52e-05	0.00129	CcSEcCtD
Methylprednisolone—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	7.45e-05	0.00127	CcSEcCtD
Methylprednisolone—Hiccups—Doxorubicin—uterine cancer	7.42e-05	0.00127	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	7.39e-05	0.00126	CcSEcCtD
Methylprednisolone—Myalgia—Dactinomycin—uterine cancer	7.35e-05	0.00126	CcSEcCtD
Methylprednisolone—Hypersensitivity—Progesterone—uterine cancer	7.35e-05	0.00126	CcSEcCtD
Methylprednisolone—Oesophagitis—Epirubicin—uterine cancer	7.32e-05	0.00125	CcSEcCtD
Methylprednisolone—Discomfort—Dactinomycin—uterine cancer	7.26e-05	0.00124	CcSEcCtD
Methylprednisolone—Ecchymosis—Epirubicin—uterine cancer	7.25e-05	0.00124	CcSEcCtD
Methylprednisolone—Urticaria—Medroxyprogesterone Acetate—uterine cancer	7.18e-05	0.00123	CcSEcCtD
Methylprednisolone—Asthenia—Progesterone—uterine cancer	7.15e-05	0.00122	CcSEcCtD
Methylprednisolone—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	7.14e-05	0.00122	CcSEcCtD
Methylprednisolone—Pulmonary oedema—Epirubicin—uterine cancer	7.13e-05	0.00122	CcSEcCtD
Methylprednisolone—Skin exfoliation—Doxorubicin—uterine cancer	7.08e-05	0.00121	CcSEcCtD
Methylprednisolone—Pruritus—Progesterone—uterine cancer	7.05e-05	0.00121	CcSEcCtD
Methylprednisolone—Fluid retention—Doxorubicin—uterine cancer	7.04e-05	0.0012	CcSEcCtD
Methylprednisolone—Infection—Dactinomycin—uterine cancer	7e-05	0.0012	CcSEcCtD
Methylprednisolone—Neuropathy—Doxorubicin—uterine cancer	6.96e-05	0.00119	CcSEcCtD
Methylprednisolone—Diarrhoea—Progesterone—uterine cancer	6.82e-05	0.00117	CcSEcCtD
Methylprednisolone—Oesophagitis—Doxorubicin—uterine cancer	6.78e-05	0.00116	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Epirubicin—uterine cancer	6.72e-05	0.00115	CcSEcCtD
Methylprednisolone—Eye disorder—Etoposide—uterine cancer	6.71e-05	0.00115	CcSEcCtD
Methylprednisolone—Ecchymosis—Doxorubicin—uterine cancer	6.7e-05	0.00115	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Epirubicin—uterine cancer	6.69e-05	0.00114	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	6.69e-05	0.00114	CcSEcCtD
Methylprednisolone—Cardiac disorder—Etoposide—uterine cancer	6.66e-05	0.00114	CcSEcCtD
Methylprednisolone—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	6.66e-05	0.00114	CcSEcCtD
Methylprednisolone—Pulmonary oedema—Doxorubicin—uterine cancer	6.6e-05	0.00113	CcSEcCtD
Methylprednisolone—Dizziness—Progesterone—uterine cancer	6.59e-05	0.00113	CcSEcCtD
Methylprednisolone—Angiopathy—Etoposide—uterine cancer	6.51e-05	0.00111	CcSEcCtD
Methylprednisolone—Immune system disorder—Etoposide—uterine cancer	6.48e-05	0.00111	CcSEcCtD
Methylprednisolone—Asthenia—Medroxyprogesterone Acetate—uterine cancer	6.48e-05	0.00111	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Etoposide—uterine cancer	6.47e-05	0.00111	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Dactinomycin—uterine cancer	6.42e-05	0.0011	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Epirubicin—uterine cancer	6.41e-05	0.0011	CcSEcCtD
Methylprednisolone—Pruritus—Medroxyprogesterone Acetate—uterine cancer	6.39e-05	0.00109	CcSEcCtD
Methylprednisolone—Vomiting—Progesterone—uterine cancer	6.34e-05	0.00108	CcSEcCtD
Methylprednisolone—Rash—Progesterone—uterine cancer	6.29e-05	0.00108	CcSEcCtD
Methylprednisolone—Dermatitis—Progesterone—uterine cancer	6.28e-05	0.00107	CcSEcCtD
Methylprednisolone—Headache—Progesterone—uterine cancer	6.25e-05	0.00107	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Doxorubicin—uterine cancer	6.22e-05	0.00106	CcSEcCtD
Methylprednisolone—Increased appetite—Epirubicin—uterine cancer	6.19e-05	0.00106	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	6.19e-05	0.00106	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Doxorubicin—uterine cancer	6.19e-05	0.00106	CcSEcCtD
Methylprednisolone—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	6.18e-05	0.00106	CcSEcCtD
Methylprednisolone—Fatigue—Dactinomycin—uterine cancer	6.08e-05	0.00104	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Epirubicin—uterine cancer	6.01e-05	0.00103	CcSEcCtD
Methylprednisolone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	5.97e-05	0.00102	CcSEcCtD
Methylprednisolone—Cardiac failure—Epirubicin—uterine cancer	5.96e-05	0.00102	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Doxorubicin—uterine cancer	5.94e-05	0.00102	CcSEcCtD
Methylprednisolone—Nausea—Progesterone—uterine cancer	5.92e-05	0.00101	CcSEcCtD
Methylprednisolone—Osteoarthritis—Epirubicin—uterine cancer	5.82e-05	0.000995	CcSEcCtD
Methylprednisolone—Feeling abnormal—Dactinomycin—uterine cancer	5.81e-05	0.000994	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Etoposide—uterine cancer	5.8e-05	0.000992	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Dactinomycin—uterine cancer	5.76e-05	0.000986	CcSEcCtD
Methylprednisolone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	5.74e-05	0.000983	CcSEcCtD
Methylprednisolone—Increased appetite—Doxorubicin—uterine cancer	5.73e-05	0.00098	CcSEcCtD
Methylprednisolone—Affect lability—Epirubicin—uterine cancer	5.73e-05	0.00098	CcSEcCtD
Methylprednisolone—Rash—Medroxyprogesterone Acetate—uterine cancer	5.7e-05	0.000975	CcSEcCtD
Methylprednisolone—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	5.69e-05	0.000974	CcSEcCtD
Methylprednisolone—Headache—Medroxyprogesterone Acetate—uterine cancer	5.66e-05	0.000969	CcSEcCtD
Methylprednisolone—Malaise—Etoposide—uterine cancer	5.64e-05	0.000964	CcSEcCtD
Methylprednisolone—Vertigo—Etoposide—uterine cancer	5.62e-05	0.000961	CcSEcCtD
Methylprednisolone—Abdominal pain—Dactinomycin—uterine cancer	5.57e-05	0.000953	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Doxorubicin—uterine cancer	5.56e-05	0.000952	CcSEcCtD
Methylprednisolone—Cardiac arrest—Epirubicin—uterine cancer	5.53e-05	0.000947	CcSEcCtD
Methylprednisolone—Cardiac failure—Doxorubicin—uterine cancer	5.52e-05	0.000944	CcSEcCtD
Methylprednisolone—Mood swings—Epirubicin—uterine cancer	5.51e-05	0.000943	CcSEcCtD
Methylprednisolone—Loss of consciousness—Etoposide—uterine cancer	5.49e-05	0.00094	CcSEcCtD
Methylprednisolone—Convulsion—Etoposide—uterine cancer	5.42e-05	0.000927	CcSEcCtD
Methylprednisolone—Hypertension—Etoposide—uterine cancer	5.4e-05	0.000923	CcSEcCtD
Methylprednisolone—Osteoarthritis—Doxorubicin—uterine cancer	5.38e-05	0.000921	CcSEcCtD
Methylprednisolone—Nausea—Medroxyprogesterone Acetate—uterine cancer	5.37e-05	0.000918	CcSEcCtD
Methylprednisolone—Affect lability—Doxorubicin—uterine cancer	5.3e-05	0.000907	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	5.28e-05	0.000904	CcSEcCtD
Methylprednisolone—Discomfort—Etoposide—uterine cancer	5.26e-05	0.0009	CcSEcCtD
Methylprednisolone—Breast disorder—Epirubicin—uterine cancer	5.26e-05	0.0009	CcSEcCtD
Methylprednisolone—Dexamethasone—CYP19A1—uterine cancer	5.26e-05	0.0336	CrCbGaD
Methylprednisolone—Hypersensitivity—Dactinomycin—uterine cancer	5.19e-05	0.000888	CcSEcCtD
Methylprednisolone—Confusional state—Etoposide—uterine cancer	5.14e-05	0.00088	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Epirubicin—uterine cancer	5.13e-05	0.000878	CcSEcCtD
Methylprednisolone—Muscular weakness—Epirubicin—uterine cancer	5.13e-05	0.000878	CcSEcCtD
Methylprednisolone—Cardiac arrest—Doxorubicin—uterine cancer	5.12e-05	0.000876	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Etoposide—uterine cancer	5.1e-05	0.000873	CcSEcCtD
Methylprednisolone—Mood swings—Doxorubicin—uterine cancer	5.1e-05	0.000873	CcSEcCtD
Methylprednisolone—Infection—Etoposide—uterine cancer	5.07e-05	0.000867	CcSEcCtD
Methylprednisolone—Abdominal distension—Epirubicin—uterine cancer	5.06e-05	0.000866	CcSEcCtD
Methylprednisolone—Asthenia—Dactinomycin—uterine cancer	5.06e-05	0.000865	CcSEcCtD
Methylprednisolone—Tachycardia—Etoposide—uterine cancer	4.98e-05	0.000852	CcSEcCtD
Methylprednisolone—Skin disorder—Etoposide—uterine cancer	4.95e-05	0.000848	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Etoposide—uterine cancer	4.93e-05	0.000844	CcSEcCtD
Methylprednisolone—Pancreatitis—Epirubicin—uterine cancer	4.93e-05	0.000844	CcSEcCtD
Methylprednisolone—Breast disorder—Doxorubicin—uterine cancer	4.86e-05	0.000832	CcSEcCtD
Methylprednisolone—Diarrhoea—Dactinomycin—uterine cancer	4.82e-05	0.000825	CcSEcCtD
Methylprednisolone—Hypotension—Etoposide—uterine cancer	4.77e-05	0.000816	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Doxorubicin—uterine cancer	4.75e-05	0.000812	CcSEcCtD
Methylprednisolone—Muscular weakness—Doxorubicin—uterine cancer	4.75e-05	0.000812	CcSEcCtD
Methylprednisolone—Abdominal distension—Doxorubicin—uterine cancer	4.68e-05	0.000801	CcSEcCtD
Methylprednisolone—Paraesthesia—Etoposide—uterine cancer	4.58e-05	0.000784	CcSEcCtD
Methylprednisolone—Weight increased—Epirubicin—uterine cancer	4.58e-05	0.000783	CcSEcCtD
Methylprednisolone—Pancreatitis—Doxorubicin—uterine cancer	4.56e-05	0.00078	CcSEcCtD
Methylprednisolone—Infestation—Epirubicin—uterine cancer	4.48e-05	0.000767	CcSEcCtD
Methylprednisolone—Infestation NOS—Epirubicin—uterine cancer	4.48e-05	0.000767	CcSEcCtD
Methylprednisolone—Vomiting—Dactinomycin—uterine cancer	4.48e-05	0.000767	CcSEcCtD
Methylprednisolone—Rash—Dactinomycin—uterine cancer	4.44e-05	0.00076	CcSEcCtD
Methylprednisolone—Fatigue—Etoposide—uterine cancer	4.4e-05	0.000752	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Epirubicin—uterine cancer	4.39e-05	0.000752	CcSEcCtD
Methylprednisolone—Sweating—Epirubicin—uterine cancer	4.3e-05	0.000735	CcSEcCtD
Methylprednisolone—Weight increased—Doxorubicin—uterine cancer	4.23e-05	0.000724	CcSEcCtD
Methylprednisolone—Feeling abnormal—Etoposide—uterine cancer	4.2e-05	0.000719	CcSEcCtD
Methylprednisolone—Nausea—Dactinomycin—uterine cancer	4.19e-05	0.000716	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Etoposide—uterine cancer	4.17e-05	0.000714	CcSEcCtD
Methylprednisolone—Infestation NOS—Doxorubicin—uterine cancer	4.15e-05	0.00071	CcSEcCtD
Methylprednisolone—Infestation—Doxorubicin—uterine cancer	4.15e-05	0.00071	CcSEcCtD
Methylprednisolone—NR3C1—myometrium—uterine cancer	4.15e-05	0.0709	CbGeAlD
Methylprednisolone—Bradycardia—Epirubicin—uterine cancer	4.1e-05	0.000701	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Doxorubicin—uterine cancer	4.07e-05	0.000696	CcSEcCtD
Methylprednisolone—Urticaria—Etoposide—uterine cancer	4.05e-05	0.000693	CcSEcCtD
Methylprednisolone—Haemoglobin—Epirubicin—uterine cancer	4.04e-05	0.000692	CcSEcCtD
Methylprednisolone—Rhinitis—Epirubicin—uterine cancer	4.03e-05	0.00069	CcSEcCtD
Methylprednisolone—Abdominal pain—Etoposide—uterine cancer	4.03e-05	0.00069	CcSEcCtD
Methylprednisolone—Haemorrhage—Epirubicin—uterine cancer	4.02e-05	0.000689	CcSEcCtD
Methylprednisolone—Sweating—Doxorubicin—uterine cancer	3.98e-05	0.00068	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Epirubicin—uterine cancer	3.95e-05	0.000677	CcSEcCtD
Methylprednisolone—Visual impairment—Epirubicin—uterine cancer	3.88e-05	0.000664	CcSEcCtD
Methylprednisolone—Bradycardia—Doxorubicin—uterine cancer	3.79e-05	0.000649	CcSEcCtD
Methylprednisolone—Eye disorder—Epirubicin—uterine cancer	3.76e-05	0.000644	CcSEcCtD
Methylprednisolone—Hypersensitivity—Etoposide—uterine cancer	3.76e-05	0.000643	CcSEcCtD
Methylprednisolone—Haemoglobin—Doxorubicin—uterine cancer	3.74e-05	0.00064	CcSEcCtD
Methylprednisolone—Cardiac disorder—Epirubicin—uterine cancer	3.74e-05	0.000639	CcSEcCtD
Methylprednisolone—Rhinitis—Doxorubicin—uterine cancer	3.73e-05	0.000639	CcSEcCtD
Methylprednisolone—Haemorrhage—Doxorubicin—uterine cancer	3.72e-05	0.000637	CcSEcCtD
Methylprednisolone—Asthenia—Etoposide—uterine cancer	3.66e-05	0.000626	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Doxorubicin—uterine cancer	3.66e-05	0.000626	CcSEcCtD
Methylprednisolone—Angiopathy—Epirubicin—uterine cancer	3.65e-05	0.000625	CcSEcCtD
Methylprednisolone—Immune system disorder—Epirubicin—uterine cancer	3.64e-05	0.000622	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Epirubicin—uterine cancer	3.63e-05	0.000621	CcSEcCtD
Methylprednisolone—Pruritus—Etoposide—uterine cancer	3.61e-05	0.000617	CcSEcCtD
Methylprednisolone—Arrhythmia—Epirubicin—uterine cancer	3.6e-05	0.000615	CcSEcCtD
Methylprednisolone—Visual impairment—Doxorubicin—uterine cancer	3.59e-05	0.000614	CcSEcCtD
Methylprednisolone—Mental disorder—Epirubicin—uterine cancer	3.53e-05	0.000603	CcSEcCtD
Methylprednisolone—Erythema—Epirubicin—uterine cancer	3.5e-05	0.000599	CcSEcCtD
Methylprednisolone—Malnutrition—Epirubicin—uterine cancer	3.5e-05	0.000599	CcSEcCtD
Methylprednisolone—Diarrhoea—Etoposide—uterine cancer	3.49e-05	0.000597	CcSEcCtD
Methylprednisolone—Eye disorder—Doxorubicin—uterine cancer	3.48e-05	0.000595	CcSEcCtD
Methylprednisolone—Cardiac disorder—Doxorubicin—uterine cancer	3.46e-05	0.000591	CcSEcCtD
Methylprednisolone—Angiopathy—Doxorubicin—uterine cancer	3.38e-05	0.000578	CcSEcCtD
Methylprednisolone—Dizziness—Etoposide—uterine cancer	3.37e-05	0.000577	CcSEcCtD
Methylprednisolone—Immune system disorder—Doxorubicin—uterine cancer	3.36e-05	0.000576	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Doxorubicin—uterine cancer	3.36e-05	0.000574	CcSEcCtD
Methylprednisolone—Arrhythmia—Doxorubicin—uterine cancer	3.33e-05	0.000569	CcSEcCtD
Methylprednisolone—Mental disorder—Doxorubicin—uterine cancer	3.26e-05	0.000558	CcSEcCtD
Methylprednisolone—NR3C1—epithelium—uterine cancer	3.26e-05	0.0557	CbGeAlD
Methylprednisolone—Ill-defined disorder—Epirubicin—uterine cancer	3.25e-05	0.000556	CcSEcCtD
Methylprednisolone—Vomiting—Etoposide—uterine cancer	3.24e-05	0.000555	CcSEcCtD
Methylprednisolone—Malnutrition—Doxorubicin—uterine cancer	3.24e-05	0.000555	CcSEcCtD
Methylprednisolone—Erythema—Doxorubicin—uterine cancer	3.24e-05	0.000555	CcSEcCtD
Methylprednisolone—NR3C1—uterine cervix—uterine cancer	3.23e-05	0.0552	CbGeAlD
Methylprednisolone—Rash—Etoposide—uterine cancer	3.22e-05	0.00055	CcSEcCtD
Methylprednisolone—Dermatitis—Etoposide—uterine cancer	3.21e-05	0.00055	CcSEcCtD
Methylprednisolone—Headache—Etoposide—uterine cancer	3.2e-05	0.000547	CcSEcCtD
Methylprednisolone—Malaise—Epirubicin—uterine cancer	3.16e-05	0.000541	CcSEcCtD
Methylprednisolone—Vertigo—Epirubicin—uterine cancer	3.15e-05	0.000539	CcSEcCtD
Methylprednisolone—Syncope—Epirubicin—uterine cancer	3.14e-05	0.000538	CcSEcCtD
Methylprednisolone—NR3C1—smooth muscle tissue—uterine cancer	3.14e-05	0.0536	CbGeAlD
Methylprednisolone—Loss of consciousness—Epirubicin—uterine cancer	3.08e-05	0.000527	CcSEcCtD
Methylprednisolone—NR3C1—decidua—uterine cancer	3.08e-05	0.0526	CbGeAlD
Methylprednisolone—Convulsion—Epirubicin—uterine cancer	3.04e-05	0.000519	CcSEcCtD
Methylprednisolone—Nausea—Etoposide—uterine cancer	3.03e-05	0.000518	CcSEcCtD
Methylprednisolone—Hypertension—Epirubicin—uterine cancer	3.02e-05	0.000518	CcSEcCtD
Methylprednisolone—NR3C1—renal system—uterine cancer	3.02e-05	0.0516	CbGeAlD
Methylprednisolone—Ill-defined disorder—Doxorubicin—uterine cancer	3.01e-05	0.000515	CcSEcCtD
Methylprednisolone—Myalgia—Epirubicin—uterine cancer	2.98e-05	0.00051	CcSEcCtD
Methylprednisolone—Arthralgia—Epirubicin—uterine cancer	2.98e-05	0.00051	CcSEcCtD
Methylprednisolone—Anxiety—Epirubicin—uterine cancer	2.97e-05	0.000509	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	2.96e-05	0.000507	CcSEcCtD
Methylprednisolone—Discomfort—Epirubicin—uterine cancer	2.95e-05	0.000504	CcSEcCtD
Methylprednisolone—Malaise—Doxorubicin—uterine cancer	2.92e-05	0.0005	CcSEcCtD
Methylprednisolone—NR3C1—endometrium—uterine cancer	2.92e-05	0.0499	CbGeAlD
Methylprednisolone—Vertigo—Doxorubicin—uterine cancer	2.91e-05	0.000498	CcSEcCtD
Methylprednisolone—Syncope—Doxorubicin—uterine cancer	2.91e-05	0.000497	CcSEcCtD
Methylprednisolone—Confusional state—Epirubicin—uterine cancer	2.88e-05	0.000493	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Epirubicin—uterine cancer	2.86e-05	0.000489	CcSEcCtD
Methylprednisolone—Loss of consciousness—Doxorubicin—uterine cancer	2.85e-05	0.000488	CcSEcCtD
Methylprednisolone—Infection—Epirubicin—uterine cancer	2.84e-05	0.000486	CcSEcCtD
Methylprednisolone—NR3C1—mammalian vulva—uterine cancer	2.82e-05	0.0483	CbGeAlD
Methylprednisolone—Shock—Epirubicin—uterine cancer	2.81e-05	0.000481	CcSEcCtD
Methylprednisolone—Convulsion—Doxorubicin—uterine cancer	2.81e-05	0.000481	CcSEcCtD
Methylprednisolone—Nervous system disorder—Epirubicin—uterine cancer	2.8e-05	0.00048	CcSEcCtD
Methylprednisolone—Hypertension—Doxorubicin—uterine cancer	2.8e-05	0.000479	CcSEcCtD
Methylprednisolone—Tachycardia—Epirubicin—uterine cancer	2.79e-05	0.000477	CcSEcCtD
Methylprednisolone—Skin disorder—Epirubicin—uterine cancer	2.78e-05	0.000475	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Epirubicin—uterine cancer	2.76e-05	0.000473	CcSEcCtD
Methylprednisolone—Myalgia—Doxorubicin—uterine cancer	2.76e-05	0.000472	CcSEcCtD
Methylprednisolone—Arthralgia—Doxorubicin—uterine cancer	2.76e-05	0.000472	CcSEcCtD
Methylprednisolone—Anxiety—Doxorubicin—uterine cancer	2.75e-05	0.000471	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	2.74e-05	0.000469	CcSEcCtD
Methylprednisolone—Discomfort—Doxorubicin—uterine cancer	2.73e-05	0.000467	CcSEcCtD
Methylprednisolone—NR3C1—uterus—uterine cancer	2.69e-05	0.046	CbGeAlD
Methylprednisolone—Hypotension—Epirubicin—uterine cancer	2.67e-05	0.000457	CcSEcCtD
Methylprednisolone—Confusional state—Doxorubicin—uterine cancer	2.67e-05	0.000456	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Doxorubicin—uterine cancer	2.65e-05	0.000453	CcSEcCtD
Methylprednisolone—Infection—Doxorubicin—uterine cancer	2.63e-05	0.00045	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Epirubicin—uterine cancer	2.61e-05	0.000446	CcSEcCtD
Methylprednisolone—Shock—Doxorubicin—uterine cancer	2.6e-05	0.000445	CcSEcCtD
Methylprednisolone—Nervous system disorder—Doxorubicin—uterine cancer	2.59e-05	0.000444	CcSEcCtD
Methylprednisolone—Insomnia—Epirubicin—uterine cancer	2.59e-05	0.000442	CcSEcCtD
Methylprednisolone—Tachycardia—Doxorubicin—uterine cancer	2.58e-05	0.000442	CcSEcCtD
Methylprednisolone—Skin disorder—Doxorubicin—uterine cancer	2.57e-05	0.00044	CcSEcCtD
Methylprednisolone—Paraesthesia—Epirubicin—uterine cancer	2.57e-05	0.000439	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Doxorubicin—uterine cancer	2.56e-05	0.000438	CcSEcCtD
Methylprednisolone—Dyspepsia—Epirubicin—uterine cancer	2.52e-05	0.000431	CcSEcCtD
Methylprednisolone—Hypotension—Doxorubicin—uterine cancer	2.47e-05	0.000423	CcSEcCtD
Methylprednisolone—Fatigue—Epirubicin—uterine cancer	2.47e-05	0.000422	CcSEcCtD
Methylprednisolone—NR3C1—female reproductive system—uterine cancer	2.42e-05	0.0413	CbGeAlD
Methylprednisolone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	2.41e-05	0.000412	CcSEcCtD
Methylprednisolone—Insomnia—Doxorubicin—uterine cancer	2.39e-05	0.000409	CcSEcCtD
Methylprednisolone—Paraesthesia—Doxorubicin—uterine cancer	2.38e-05	0.000406	CcSEcCtD
Methylprednisolone—Feeling abnormal—Epirubicin—uterine cancer	2.36e-05	0.000403	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Epirubicin—uterine cancer	2.34e-05	0.0004	CcSEcCtD
Methylprednisolone—Dyspepsia—Doxorubicin—uterine cancer	2.33e-05	0.000398	CcSEcCtD
Methylprednisolone—CYP3A4—renal system—uterine cancer	2.28e-05	0.039	CbGeAlD
Methylprednisolone—Fatigue—Doxorubicin—uterine cancer	2.28e-05	0.00039	CcSEcCtD
Methylprednisolone—Urticaria—Epirubicin—uterine cancer	2.27e-05	0.000389	CcSEcCtD
Methylprednisolone—Abdominal pain—Epirubicin—uterine cancer	2.26e-05	0.000387	CcSEcCtD
Methylprednisolone—ABCB1—myometrium—uterine cancer	2.22e-05	0.038	CbGeAlD
Methylprednisolone—NR3C1—female gonad—uterine cancer	2.2e-05	0.0376	CbGeAlD
Methylprednisolone—NR3C1—vagina—uterine cancer	2.19e-05	0.0374	CbGeAlD
Methylprednisolone—Feeling abnormal—Doxorubicin—uterine cancer	2.18e-05	0.000373	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Doxorubicin—uterine cancer	2.16e-05	0.00037	CcSEcCtD
Methylprednisolone—Hypersensitivity—Epirubicin—uterine cancer	2.11e-05	0.00036	CcSEcCtD
Methylprednisolone—Urticaria—Doxorubicin—uterine cancer	2.1e-05	0.00036	CcSEcCtD
Methylprednisolone—Abdominal pain—Doxorubicin—uterine cancer	2.09e-05	0.000358	CcSEcCtD
Methylprednisolone—Asthenia—Epirubicin—uterine cancer	2.05e-05	0.000351	CcSEcCtD
Methylprednisolone—Pruritus—Epirubicin—uterine cancer	2.02e-05	0.000346	CcSEcCtD
Methylprednisolone—Diarrhoea—Epirubicin—uterine cancer	1.96e-05	0.000335	CcSEcCtD
Methylprednisolone—Hypersensitivity—Doxorubicin—uterine cancer	1.95e-05	0.000334	CcSEcCtD
Methylprednisolone—Asthenia—Doxorubicin—uterine cancer	1.9e-05	0.000325	CcSEcCtD
Methylprednisolone—Dizziness—Epirubicin—uterine cancer	1.89e-05	0.000324	CcSEcCtD
Methylprednisolone—Pruritus—Doxorubicin—uterine cancer	1.87e-05	0.00032	CcSEcCtD
Methylprednisolone—CYP3A4—female reproductive system—uterine cancer	1.83e-05	0.0313	CbGeAlD
Methylprednisolone—Vomiting—Epirubicin—uterine cancer	1.82e-05	0.000311	CcSEcCtD
Methylprednisolone—Diarrhoea—Doxorubicin—uterine cancer	1.81e-05	0.00031	CcSEcCtD
Methylprednisolone—Rash—Epirubicin—uterine cancer	1.8e-05	0.000308	CcSEcCtD
Methylprednisolone—Dermatitis—Epirubicin—uterine cancer	1.8e-05	0.000308	CcSEcCtD
Methylprednisolone—Headache—Epirubicin—uterine cancer	1.79e-05	0.000306	CcSEcCtD
Methylprednisolone—Dizziness—Doxorubicin—uterine cancer	1.75e-05	0.000299	CcSEcCtD
Methylprednisolone—ABCB1—epithelium—uterine cancer	1.74e-05	0.0298	CbGeAlD
Methylprednisolone—ABCB1—uterine cervix—uterine cancer	1.73e-05	0.0295	CbGeAlD
Methylprednisolone—Nausea—Epirubicin—uterine cancer	1.7e-05	0.000291	CcSEcCtD
Methylprednisolone—Vomiting—Doxorubicin—uterine cancer	1.68e-05	0.000288	CcSEcCtD
Methylprednisolone—Rash—Doxorubicin—uterine cancer	1.67e-05	0.000285	CcSEcCtD
Methylprednisolone—Dermatitis—Doxorubicin—uterine cancer	1.67e-05	0.000285	CcSEcCtD
Methylprednisolone—Headache—Doxorubicin—uterine cancer	1.66e-05	0.000284	CcSEcCtD
Methylprednisolone—ABCB1—decidua—uterine cancer	1.65e-05	0.0281	CbGeAlD
Methylprednisolone—ABCB1—renal system—uterine cancer	1.62e-05	0.0276	CbGeAlD
Methylprednisolone—Nausea—Doxorubicin—uterine cancer	1.57e-05	0.000269	CcSEcCtD
Methylprednisolone—ABCB1—endometrium—uterine cancer	1.56e-05	0.0267	CbGeAlD
Methylprednisolone—ABCB1—mammalian vulva—uterine cancer	1.51e-05	0.0258	CbGeAlD
Methylprednisolone—ABCB1—uterus—uterine cancer	1.44e-05	0.0246	CbGeAlD
Methylprednisolone—NR3C1—lymph node—uterine cancer	1.41e-05	0.0242	CbGeAlD
Methylprednisolone—ABCB1—female reproductive system—uterine cancer	1.29e-05	0.0221	CbGeAlD
Methylprednisolone—ABCB1—female gonad—uterine cancer	1.18e-05	0.0201	CbGeAlD
Methylprednisolone—ABCB1—vagina—uterine cancer	1.17e-05	0.02	CbGeAlD
Methylprednisolone—ABCB1—lymph node—uterine cancer	7.57e-06	0.0129	CbGeAlD
